TY - JOUR
T1 - Tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel (3T/2R). Rationale for the study and protocol design
AU - Valgimigli, Marco
AU - Campo, Gianluca
AU - De Cesare, Nicoletta
AU - Vranckx, Pascal
AU - Hamon, Martial
AU - Angiolillo, Dominick J.
AU - Sabatè, Manel
AU - Ferrari, Fabrizio
AU - Furgieri, Alessandro
AU - Tumscitz, Carlo
AU - Repetto, Alessandra
AU - Colangelo, Salvatore
AU - Meliga, Emanuele
AU - Kubbajeh, Moh'd
AU - Parrinello, Giovanni
AU - Percoco, Gianfranco
AU - Ferrari, Roberto
PY - 2008/8
Y1 - 2008/8
N2 - Purpose: To assess whether glycoprotein IIb/IIIa inhibition using tirofiban in low risk patients undergoing percutaneous coronary intervention (PCI) may reduce the risk of periprocedural myocardial infarction compared to standard care in poor responders to aspirin and/or clopidogrel. Methods: We will enroll patients at ten European sites or more to participate in the Tailoring Treatment with Tirofiban in patients showing Resistance to aspirin and/or Resistance to clopidogrel (3T/2R) study with a pre-specified sample size of 240 patients out of 1,100 or more who will undergo screening. The primary outcome measure is troponin I or T elevation ratio at least three times the upper limit of normal within 48 h after completion of the PCI. Conclusion: The results of 3T/2R study will evaluate whether tailored intensification of anti-platelet treatment based on poor individual response to oral anti-platelet agents may modulate the risk of periprocedural myocardial infarction during PCI. Our findings attempt at unraveling a new era of individualized anti-platelet treatment through the use of point-of-care assessment.
AB - Purpose: To assess whether glycoprotein IIb/IIIa inhibition using tirofiban in low risk patients undergoing percutaneous coronary intervention (PCI) may reduce the risk of periprocedural myocardial infarction compared to standard care in poor responders to aspirin and/or clopidogrel. Methods: We will enroll patients at ten European sites or more to participate in the Tailoring Treatment with Tirofiban in patients showing Resistance to aspirin and/or Resistance to clopidogrel (3T/2R) study with a pre-specified sample size of 240 patients out of 1,100 or more who will undergo screening. The primary outcome measure is troponin I or T elevation ratio at least three times the upper limit of normal within 48 h after completion of the PCI. Conclusion: The results of 3T/2R study will evaluate whether tailored intensification of anti-platelet treatment based on poor individual response to oral anti-platelet agents may modulate the risk of periprocedural myocardial infarction during PCI. Our findings attempt at unraveling a new era of individualized anti-platelet treatment through the use of point-of-care assessment.
KW - Aspirin resistance
KW - Clopidogrel resistance
KW - Platelet inhibition
KW - Tirofiban
UR - http://www.scopus.com/inward/record.url?scp=48349103357&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=48349103357&partnerID=8YFLogxK
U2 - 10.1007/s10557-008-6121-z
DO - 10.1007/s10557-008-6121-z
M3 - Article
C2 - 18561010
AN - SCOPUS:48349103357
SN - 0920-3206
VL - 22
SP - 313
EP - 320
JO - Cardiovascular Drugs and Therapy
JF - Cardiovascular Drugs and Therapy
IS - 4
ER -